Diamyd Medical is a pharmaceutical company based in Stockholm that specializes in developing precision therapies for type 1 diabetes. The company is actively engaged in pharmaceutical development and is currently conducting the Phase 3 trial known as DIAGNODE-3, which is part of its ongoing clinical trials aimed at improving diabetes treatment. Diamyd Medical focuses on intralymphatic immunotherapy and offers the Diamyd® therapy as part of its treatment options.
The company is listed on Nasdaq Stockholm First North under the ticker DMYD B. Diamyd Medical provides updates on its progress and developments through press releases, ensuring that stakeholders are informed about its activities. Additionally, the company hosts events and maintains a media watch to engage with its stakeholders, reflecting its commitment to advancing diabetes care and research.